A new study confirms the accuracy of the European Association of Urology (EAU) risk classification system for prostate cancer patients, using PSMA PET imaging to identify subgroups with varying disease risks. High-risk groups showed higher metastatic disease rates, while low-risk groups had undetectable or distant metastases.
A new PET/CT artificial intelligence model has been developed to predict the risk of future heart attacks with improved accuracy. By combining information from PET and CT angiography, the model provides a more robust prediction of heart attack risk than clinical data alone.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for prostate-specific membrane antigen (PSMA) PET imaging. The guidelines provide a framework for healthcare providers to determine the most effective use of PSMA PET scans in patients with suspected or known prostate cancer.
A new Journal of Nuclear Medicine supplement explores personalization of patient treatment through radiopharmaceutical dosimetry, addressing its benefits and challenges. The study reveals that tailoring drug dosage can enhance the efficacy of radiopharmaceutical therapy for cancer patients.
A new type of PRRT, <sup> 177 </sup> Lu-DOTA-LM3, has been shown to be safe and effective in treating neuroendocrine neoplasms. The therapy achieved complete remission in some patients and was well-tolerated by most patients.
A recent study suggests that Long-COVID symptoms, such as cognitive deficits and fatigue, may be attributed to fatigue rather than pathological changes in the brain. Neuroimaging results showed no significant differences in cerebral glucose metabolism or brain pathology between patients with long-COVID and healthy controls.
A study published in The Journal of Nuclear Medicine found that PSMA PET/CT is more accurate than conventional CT in detecting hepatocellular carcinoma metastases. This led to a change in management plans for nearly half of the patients, enabling them to receive effective treatment.
A new PET imaging agent has been shown to solve 87% of diagnostic dilemmas in breast cancer patients, providing valuable information for personalized treatment decision-making. The agent's ability to visualize estrogen receptor expression across the body may improve patient outcomes and support broader implementation in clinical practice.
A promising radionuclide treatment has been identified for HER2-positive breast cancer patients, combining radioactive iodine therapy with single-domain antibodies targeting the HER2 antigen. The treatment demonstrates safety and efficacy in a phase I study, paving the way for further clinical development.
Researchers developed a topical fluorescent imaging agent targeting PARP1 enzyme in cervical cancer cells, enabling real-time detection with handheld microscopes. This non-invasive method could revolutionize cervical cancer screenings and biopsies, especially in low-resource areas.
A new radiotracer, 18F-TRX, has been developed to measure iron concentration in tumors, predicting treatment response. The agent successfully distinguished between tumor types and identified those likely to respond to iron-targeted therapies.
The uEXPLORER total-body PET/CT scanner has been evaluated for its performance exceeding industry standards with ultra-high sensitivity and excellent spatial resolution. The study also proposed new phantom measurements to characterize long-AFOV scanners, enabling the testing of their performance in improving patient care.
The study found that 68Ga-FAPI PET/CT imaging can improve restaging of disease in more than half of patients with pancreatic ductal adenocarcinomas, particularly those with local recurrence. This new imaging modality may help detect new or clarify inconclusive results obtained by standard CT imaging.
Researchers found deficits in neuronal function and cognitive impairment in newly diagnosed COVID-19 patients, with some impairments continuing six months after diagnosis. PET brain scans showed a significant recovery of regional neuronal function and cognition in most patients.
Researchers developed a novel PET tracer to detect abdominal aortic aneurysms (AAAs) and predict rupture risk. The tracer, targeting chemokine receptor type 2 (CCR2), showed safety and effectiveness in diagnosing AAAs and assessing treatment response.
A phase III clinical trial validates the effectiveness of 18F-DCFPyL in detecting and localizing recurrent prostate cancer, achieving high positive predictive values across various regions. The study's results support the use of PSMA-targeted radiotracers as the most sensitive and accurate agents for imaging prostate cancer.
A novel PET radiotracer detects increases in brain tau, a hallmark of Alzheimer's disease, up to 12 months before symptoms emerge. This allows for effective selection of patients for clinical trials, potentially speeding the development of treatments.
Dr. Thomas J. Ruth is recognized for his significant contributions to nuclear medicine, including the development of radioisotopes for positron emission tomography (PET) imaging. He has been a leader in radiopharmaceutical sciences for over four decades and has mentored numerous scientists in the field.
Researchers have developed a novel cancer treatment approach that utilizes Cerenkov radiation energy to activate semiconducting polymer nanoparticles, killing cancer cells. The approach amplifies weak Cerenkov luminescence with semiconducting polymers, increasing its potential to target and destroy cancer cells.
Research found that lipophilic statins double the risk of developing dementia in patients with mild cognitive impairment. PET scans revealed a decline in brain metabolism, particularly in the posterior cingulate cortex.
A new radiopharmaceutical, 18F-DASA-23, has successfully visualized the 'master switch' protein PKM2 in glioblastoma patients. This allows for non-invasive assessment of treatment response and potential early detection of therapeutic effectiveness.
Dr. Larson has been named recipient of the prestigious Paul C. Aebersold Award for his contributions to cancer imaging and radionuclide therapy. He is a world-renowned expert in radiopharmaceutical therapy and molecular imaging.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced 17 new Fellows, recognizing their outstanding contributions to the field. The newly elected Fellows include experts who have demonstrated excellence in scientific discovery, educational efforts, and clinical practice.
Researchers developed a super-resolution technique that harnesses unwanted head motion to enhance brain PET image resolution. This method shows promise in detecting neurological disorders like Alzheimer's disease at their earliest stages, enabling quicker diagnosis and treatment.
Researchers developed a new PET/CT radiotracer that targets activated fibroblasts in lungs, enabling direct imaging of pulmonary fibrosis. The study showed promising results, suggesting the radiotracer's potential to reduce lung biopsies and improve disease management.
Researchers developed a deep learning network using data from over 20,000 patients to predict annualized risk for heart attack or death. The network identified regions of the heart associated with high-risk patients and provided rapid risk scores.
A new radiopharmaceutical has been developed to treat ovarian cancer, dramatically limiting tumor growth and decreasing tumor mass. The treatment, which can be produced in just 25 minutes at low cost, shows promise as an efficient alternative to existing methods.
The SNMMI Virtual Annual Meeting will convene over 6,000 attendees to share breaking news and research in precision medicine, focusing on early diagnosis, effective therapy delivery, and optimized treatment monitoring. The meeting features hundreds of scientific abstracts and a cutting-edge exhibit hall.
Amino acid PET imaging improves diagnosis of recurring brain metastases and assesses patient response to new treatments. This non-invasive technique helps physicians optimize treatment strategies for patients with melanoma and lung cancer.
A new positron emission tomography (PET) tracer targeting inflammation has been shown to be safe and effective in identifying early stages of rheumatoid arthritis. The tracer rapidly clears from blood circulation and has a low radiation dose, making it suitable for patient imaging studies.
A new treatment for late-stage neuroendocrine tumors has been shown to be more effective and have fewer side effects than the current standard of care. Researchers found that a modified therapy, known as 177Lu-DOTA-EB-TATE, is safest and produces the best tumor response when given in specific doses.
Researchers have developed Immuno-PET, a technique that visualizes changes in different cancer receptors within tumors during targeted therapies, enabling early evaluation of treatment effectiveness and prediction of response. This can help physicians select the most effective treatment for patients with cancer.
Researchers used positron emission tomography (PET) imaging with 18F-fluoroestradiol to predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients. The study found that higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival.
A new study published in the Journal of Nuclear Medicine found that combining radionuclide therapy with immunotherapy can slow prostate cancer progression and increase survival time. The treatment promotes prostate cancer immunogenicity, making tumors more receptive to immunotherapy.
A new study expands the 64Cu-DOTATATE PET imaging time window to three hours post-injection, detecting similar numbers of lesions as a one-hour scan. The extended imaging time allows for more flexible routine imaging of patients with neuroendocrine neoplasms.
A study of potential jurors found they are more favorable towards physicians who accept standard AI medical recommendations. The study suggests the threat of legal liability may be smaller than commonly thought, influencing physician behavior and AI adoption.
Researchers have developed a new theranostic approach using copper radionuclides that improves survival rates and reduces tumor volume in neuroendocrine tumors. The new method produces high-quality PET images and demonstrates improved efficacy when delivered as two fractionated doses.
The Journal of Nuclear Medicine has published a special supplement commemorating six decades of leadership in the field, featuring influential manuscripts that shaped the future of medicine. The supplement highlights landmark papers on PET, Anger camera, and fusion PET/CT, as well as the journal's past editors and associate editors.
A proof-of-concept study found that 68Ga-pentixafor PET imaging effectively diagnoses and manages rare CNS B-cell lymphoma by targeting the CXCR4 biomarker. The imaging modality showed excellent contrast characteristics between lymphoma lesions and surrounding healthy brain tissue.
Researchers pooled data from multiple sites to visualize neuroinflammation in ALS patients, enhancing detection and developing drugs. The study used two second-generation translator protein tracers and found improved power to detect inflammation compared to individual site data alone.
Researchers developed a novel photodynamic therapy to target insulin-producing lesions, showing promise in slowing tumor growth and inducing cell death. The treatment could provide a minimally invasive option for hyperinsulinemic hypoglycemia, improving patient management.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab. In a non-Hodgkin's lymphoma mouse model, the treatment substantially increased rituximab binding and antibody-dependent cellular cytotoxicity activity, resulting in significant tumor growth delay.
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy by detecting prostate cancer tissue at the resection margin. CLI has shown high diagnostic accuracy in detecting tumor cells and positive surgical margins.
A single-center observational study found that PET/MRI improves lesion detectability in select cancers and significantly reduces overall radiation exposure compared to PET/CT. The study, published in The Journal of Nuclear Medicine, shows that PET/MRI can promote fast, efficient local and whole-body staging in one step.
The SNMMI Wagner-Torizuka Fellowship provides extensive training and experience for Japanese physicians in nuclear medicine and molecular imaging. The program has graduated 30 fellows since its inception and supports the worldwide advancement of nuclear medicine and molecular imaging.
Researchers developed a simplified process to estimate radiation dose using a single post-treatment SPECT/CT scan, potentially improving therapeutic outcomes by tailoring treatments to individual patients' physiology. The method was applied to 177Lu-PSMA-617 therapy for metastatic prostate cancer.
A new alpha-radioimmunotherapy has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice. The therapy targets CD38 protein on tumoral cells and reduces unwanted radiation exposure on normal tissues.
A genomic signature associates with differential expression of glucose transporters and hexokinase proteins in prostate cancers with low PSMA expression. This allows for improved uptake of 18F-FDG compared to PSMA-targeted radioligands, making it an attractive imaging tool for neuroendocrine prostate cancer patients.
Research at SNMMI 2020 Annual Meeting found super-agers have lower tau and amyloid pathology associated with neurodegeneration. This enables them to maintain their cognitive skills even at advanced ages. The study suggests a potential pathway for successful aging and developing novel treatments to tackle age-related diseases.
A novel bone imaging approach has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis. This finding provides a new functional measure to assess degeneration of the knee joint, and may help develop interventions to slow or arrest its progression.